Correlation Engine 2.0
Clear Search sequence regions


The authors investigate the effects and mechanisms of the anti-hepatitis B virus (HBV) agent Bay 41-4109. HepG2.2.15 cells were used to investigate the antiviral effects of Bay 41-4109 by using real-time polymerase chain reaction (PCR), western blotting, and immunofluorescence. The C terminally truncated core protein was expressed and purified. Changes in hepatitis B capsid formation were assayed by dynamic light scattering and transmission electronic microscopy. Bay 41-4109 was found to be a highly selective and potent inhibitor of hepatitis B virus replication in HepG2.2.15 cells. This compound was equally effective at inhibiting HBV DNA release and the cytoplasmic HBcAg level, with 50% inhibitory concentrations of 32.6 and 132 nM, respectively. HBV DNA and HBcAg were inhibited in a dose-dependent manner, indicating that the anti-HBV mechanisms are associated with and dependent on the rate of HBcAg inhibition. Our results indicate that Bay 41-4109 treatment disassembled the core capsids and separated them into monomers or dimers, the form in which they could be further degraded into peptides. The core protein assembled in a misdirected manner cannot function effectively. Our results suggest that, based on its particular activities, Bay 41-4109 is a promising anti-HBV candidate.

Citation

Guo-Yi Wu, Xiao-Jing Zheng, Chang-Cheng Yin, Dong Jiang, Ling Zhu, Yan Liu, Lai Wei, Yu Wang, Hong-Song Chen. Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly. Journal of chemotherapy (Florence, Italy). 2008 Aug;20(4):458-67

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 18676226

View Full Text